Phenytoin is a commonly prescribed antiepileptic drug. Due to its saturation (zero-order) pharmacokinetics, phenytoin carries a special risk of dose-related toxicity that is an important issue in emergency medicine. The purpose of this cross-sectional case-series study was to investigate the causes, symptoms, misdiagnoses, and outcomes of acute phenytoin intoxication. It was based on a retrospective chart review of 30 inpatients (mean age, 41.6 ± 22.8 years) with 36 episodes of acute phenytoin intoxication at our university hospital in the past 13 years. The average initial serum phenytoin level was 47.3 ± 9.7 µg/mL (range, 27.9-70.4 µg/mL). Excessive self-medication, misunderstanding of the prescription order, and probable drug interaction were the three leading causes of acute phenytoin intoxication. Unsteady gait, dizziness/vertigo, nausea/vomiting, general weakness, and drowsiness were the most common presenting symptoms. The tentative diagnostic accuracy was 67%. The most common initial misdiagnosis was brainstem or cerebellum stroke (14%). The clinical course in all patients was uneventful under temporary withdrawal of phenytoin and supportive care. We concluded that acute phenytoin intoxication was relatively under-diagnosed in the emergency service. Although acute phenytoin intoxication causes no mortality and has a good outcome, the unsteady gait increases the risk of injuries caused by falls. The management of acute phenytoin intoxication includes temporary withdrawal of phenytoin and supportive care. Phenytoin is a commonly prescribed antiepileptic drug. It is also used for the treatment of paroxysmal kinesigenic dyskinesia [1], myotonia [2] , Isaacs' syndrome [3] , and neuropathic pain [4, 5] . Phenytoin is hydroxylated and converted to the para isomer of 5-hydroxy-phenyl-5-phenylhydantoin (p-HPPH) in the liver and is excreted as the glucuronide conjugate of p-HPPH in the urine. The metabolic conversion to p-HPPH is a saturable process. The point at which saturation occurs is unpredictable and varies among individuals. Once saturated, the serum phenytoin concentration rises in a curvilinear manner. This is why small increments in dose can cause a large increase in the serum phenytoin level in many patients [6] . Phenytoin intoxication is one reason why persons with epilepsy visit the emergency department. The narrow therapeutic index, the wide inter-individual variability in the rate of phenytoin metabolism and clearance, and the saturation (zero-order) pharmacokinetics of phenytoin are responsible for the observed dose-related toxicity. The purpose of this retrospective case-series study was to investigate the causes, symptoms, misdiagnoses, and outcomes of acute phenytoin intoxication at a university hospital in southern Taiwan.
Phenytoin is a commonly prescribed antiepileptic drug. It is also used for the treatment of paroxysmal kinesigenic dyskinesia [1] , myotonia [2] , Isaacs' syndrome [3] , and neuropathic pain [4, 5] . Phenytoin is hydroxylated and converted to the para isomer of 5-hydroxy-phenyl-5-phenylhydantoin (p-HPPH) in the liver and is excreted as the glucuronide conjugate of p-HPPH in the urine. The metabolic conversion to p-HPPH is a saturable process. The point at which saturation occurs is unpredictable and varies among individuals. Once saturated, the serum phenytoin concentration rises in a curvilinear manner. This is why small increments in dose can cause a large increase in the serum phenytoin level in many patients [6] . Phenytoin intoxication is one reason why persons with epilepsy visit the emergency department. The narrow therapeutic index, the wide inter-individual variability in the rate of phenytoin metabolism and clearance, and the saturation (zero-order) pharmacokinetics of phenytoin are responsible for the observed dose-related toxicity. The purpose of this retrospective case-series study was to investigate the causes, symptoms, misdiagnoses, and outcomes of acute phenytoin intoxication at a university hospital in southern Taiwan.
PATIENTS AND METHODS
This case-series study was a retrospective chart review of inpatients. A computer-assisted search of medical records identified patients diagnosed with acute phenytoin intoxication who had been admitted to the departments of adult and pediatric neurology in our hospital in the past 13 years. Demographic data, phenytoin dose, and serum phenytoin levels were obtained from the medical records. All patients had documented serum phenytoin levels of more than 20 µg/mL, clinical evidence of toxicity at presentation, and improvement of clinical symptoms and signs after the serum phenytoin level declined to around the therapeutic level.
Serum phenytoin level was measured using a fluorescence polarization immunoassay (Abbott Laboratories Inc, Abbott Park, IL, USA). A dilution protocol was used if the serum phenytoin level was more than 40 µg/mL. Serum phenytoin levels were monitored daily following temporary discontinuation of phenytoin in 12 adults with 12 episodes. The average daily rate of decline of serum phenytoin level was derived by subtracting the serum phenytoin level nearest to 20 µg/mL from the serum phenytoin level at presentation and then dividing by the time interval (expressed in days).
RESULTS
There were 30 patients in this series: three children, four adolescents, and 23 adults (mean age, 41.6 ± 22.8 years; range, 1-79 years). Six patients had had two episodes of phenytoin intoxication and 24 had each had a single episode, giving a total of 36 episodes of phenytoin intoxication. Twenty-two patients took phenytoin as monotherapy, seven took it with one other anticonvulsant (phenobarbital in three patients, carbamazepine in one, vigabatrin in one, lamotrigine in one, and primidone in one), and one patient took phenytoin, carbamazepine, and sodium valproate at the same time. The indications for phenytoin treatment were idiopathic epilepsy (8/30, 27%), symptomatic epilepsy (21/30, 70%), and neuropathic pain (1/30, 3%).
The leading cause of phenytoin intoxication was excessive self-medication (14/36 episodes, 39%; Table 1 ) for one of several reasons: recurrence of seizures after stopping or reducing phenytoin dose by themselves; unsatisfactory seizure control with the prescribed dosage; the other concomitant anticonvulsant had been used up and an increased phenytoin dose was used as temporary monotherapy; or to prevent seizures when fatigued or sleep-deprived.
Six episodes (17%) in six patients were probably secondary to drug interaction. Four of these patients were reported to be intoxicated with phenytoin after taking or injecting some common-cold medications. One patient showed phenytoin toxicity after stopping the coadministered primidone. Another patient took phenytoin, prochlorperazine, propranolol, and clonazepam at the same time.
Five episodes (14%) in four patients were caused by misunderstanding the prescription order. Three of these episodes occurred in two patients, documented as mentally subnormal, who handled medication by themselves. Caregivers were responsible for the other two episodes in another two patients.
Iatrogenic causes of intoxication accounted for four episodes (11%) in the present study. All were caused by excessive intravenous supplementary ("booster") loading for a single seizure. One patient took phenytoin irregularly and suffered from occasional seizures, but she did not mention her poor compliance to the doctor. She was then asked to take a higher dose of phenytoin regularly and suffered from intoxication thereafter.
The time interval between phenytoin dose increments and the appearance of clinical symptoms was variable and ranged from several hours to 3 days. It was within hours for the patient who attempted suicide by taking a large amount of phenytoin and for patients intoxicated iatrogenically by excessive intravenous supplementary loading for a single seizure. The time interval was usually 1 day if the increment was 300-500 mg/day and 1-3 days if the increment was 200 mg/day.
Our patients presented with a great variety of symptoms (Table 2) . Unsteady gait was the most common (78%). Four patients suffered from falling caused by unsteady gait, two without obvious injury but two with an ear laceration wound and an eye ecchymosis, respectively. The frequency of the most common clinical symptoms and the initial serum phenytoin level is shown in Figure 1 . The less frequent symptoms, such as headache, confusion, blurred vision, and slurred speech, were noted when the initial serum phenytoin level was more than 40 µg/mL. We used the duration of hospital stay as an index of severity of phenytoin intoxication and found no significant correlation between the initial serum phenytoin level and the duration of hospital stay.
An accurate initial diagnosis of phenytoin intoxication was made in 24 (67%) of 36 episodes (Table 3) . Five episodes (14%) in four patients were initially diagnosed as brainstem or cerebellar stroke. Two of these four patients had a history of cerebrovascular disease and post-stroke epilepsy and were suspected of having recurrent brainstem or cerebellar stroke. The other two patients (3 episodes) were a 40-yearold with a medical history of diabetes mellitus and hypertension and a patient with a medical history of diabetes mellitus who had two episodes of intoxication at 67 and 71 years of age.
The mean duration of phenytoin treatment was 10.9 ± 11.8 years (range, 0.3-44 years). The average initial serum phenytoin level in the emergency service was 47.3 ± 9.7 µg/mL (range, 27.9-70.4 µg/mL). The average daily rate of decline of serum phenytoin level was 8.6 ± 1.4 µg/mL (range, 6.3-11.1 µg/mL), which was significantly correlated with the patient's regular phenytoin dosage (r = 0.68, p = 0.02; Figure 2) but not with the initial serum phenytoin level (r = 0.46, p = 0.13). This might explain why the duration of hospital stay was not significantly correlated with the initial serum phenytoin level. One patient who was intoxicated by excessive self-medication presented with an initial phenytoin level of 53 µg/mL, which rose to 63.7 µg/mL the next day and declined gradually. This was most likely due to delayed absorption of phenytoin in the gastrointestinal tract. Two patients had one seizure episode each before restarting We retrospectively documented an average of three episodes of hospitalization due to acute phenytoin intoxication per year in our hospital over a 13-year period. Vital signs were stable at presentation and through the hospital course in every patient. The mean hospital stay was 6.7 ± 2.7 days (range, 3-14 days). None of these patients had hemodynamic compromise or respiratory distress requiring intensive care. All patients were treated by temporarily discontinuing phenytoin and providing supportive care. There was no mortality in these 30 patients.
DISCUSSION
The most common cause of acute phenytoin intoxication in our series was excessive self-medication. Patient-caused intoxication is preventable if patients are adequately educated about their medication. Due to the pharmacokinetic features of phenytoin, it is suggested that physicians who treat patients with epilepsy have both low-dose phenytoin (e.g. 30 mg) and 100 mg phenytoin available. Increments of phenytoin must be given gradually, especially around the lower limit of the therapeutic range (10 µg/mL). Since phenytoin toxicity may occur before a steady state is reached, it may be prudent to monitor the patient for toxic symptoms and to consider a serum phenytoin level check-up several days (e.g. 3-5 days) after dosage initiation or adjustment [7] . Iatrogenic intoxication can also be reduced by implementing a didactic and case-based program to educate physicians about phenytoin pharmacokinetics and the loading, maintenance, adjustment, and monitoring of phenytoin therapy [7] .
To avoid misunderstanding of the prescription order, mentally subnormal patients should not be allowed to administer their own medications. Also, caregivers, especially those whose native language is not the same as that of the prescribing physician and the patient, should be given a clear translation of the order in a language in which they are fluent. Patients with uncertain compliance may be admitted for supervision before increasing their phenytoin dosage. Medications commonly used for the common cold have not been reported to increase serum phenytoin levels significantly or acutely [8] . Since the cold medications used by the four patients were not available, their cause-effect relationship cannot be determined. Drug interactions between phenytoin and primidone, prochlorperazine, propranolol, and clonazepam have been reported [6] .
Unsteady gait was the most common presenting symptom in this study, similar to a previous report [9] . Four patients suffered from falls. We suggest that bed rest or assisted ambulation is mandatory during the acute intoxication period. Under-diagnosis of phenytoin intoxication was not uncommon (12/36, 33%). The acute onset and spectrum of clinical presentations, especially the most common symptoms of unsteady gait, dizziness/ vertigo, and nausea/vomiting, may raise a suspicion of brainstem or cerebellar stroke. This is why the five episodes in our elderly subjects with risk factors for vascular disease were initially diagnosed as brainstem or cerebellar stroke. Delayed recognition of acute phenytoin intoxication in this subgroup usually leads to unnecessary or inappropriate medical intervention and concomitant deterioration of existing symptoms/signs by continuing phenytoin treatment. Presentation with relatively uncommon symptoms, an incomplete medical history, and failure to notice gum hyperplasia or nystagmus are the leading reasons for under-diagnosis of phenytoin intoxication. Hand tremor and other movement disorders are rare manifestations of phenytoin intoxication [10, 11] . A complete history, inspection for gum hyperplasia in patients with brainstem or cerebellar symptoms and signs, and knowledge of the full spectrum of clinical presentations of acute phenytoin intoxication would improve diagnostic accuracy.
The observed decline in serum phenytoin levels was 8.6 ± 1.4 µg/mL/day (range, 6.3-11.1 µg/mL/day) in 12 adults. In clinical practice, it is important to estimate how long phenytoin should be temporarily withdrawn and when phenytoin therapy might safely be restarted with a limited number of blood samples. Several case reports have shown graphically the serial serum phenytoin levels after discontinuation of phenytoin in acutely intoxicated patients without offering practical guidelines for the timing of phenytoin monitoring and the reinstitution of phenytoin [12] [13] [14] [15] [16] . The serum phenytoin half-life is concentration-dependent and previous studies have demonstrated a considerable individual variation in Michaelis-Menten parameters (maximum rate of metabolism and phenytoin level at which metabolic rate will be one-half the maximum) [17, 18] . Age, ethnicity, supervening illness, or interacting drugs have significant influence on the pharmacokinetics of phenytoin. It is therefore difficult to accurately predict the rate of decline of serum phenytoin levels in patients with acute phenytoin intoxication using a simple equation. This is also why there is still a lack of simple practical guidelines for monitoring phenytoin and reinstitution of phenytoin therapy. As our data were retrospectively assessed and there was no standardized blood sampling scheme for most patients, the observed rate of decline derived from a small number of patients (n = 12) with a wide age range (21-81 years) may not work well in clinical practice. A prospective study in newly diagnosed phenytoin-intoxicated patients is necessary to validate the clinical usefulness of a crude estimate of phenytoin decline by 8.6 ± 1.4 µg/mL/day. Perhaps a better strategy would be to measure phenytoin concentrations at presentation and 2 or 3 days later, and to consider that, at high phenytoin concentrations, the decline of phenytoin is nearly linear [17] . At a concentration of approximately 25 µg/mL, the rate of elimination is greatly increased, which results in a relatively rapid fall in the serum phenytoin concentration [12] . There were no circulatory collapses or deaths in our series. None of the patients needed intensive care. The outcomes of our patients were as good as those of patients in previous reports [19] [20] [21] . Acute intoxication by oral phenytoin rarely causes death [22, 23] . The circulatory collapse caused by intravenous phenytoin may be due to a rapid rise in serum phenytoin level or to a toxic solvent, such as propylene glycol [19] [20] [21] . We conclude that acute phenytoin intoxication was relatively under-diagnosed in the emergency service. Although acute phenytoin intoxication causes no mortality and has a good outcome, the unsteady gait increases the risk of injuries caused by falls. The management of acute phenytoin intoxication includes temporary withdrawal of phenytoin and supportive care. 
